Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Prenetics Group ( (PRE) ) has shared an update.
On February 17, 2026, Prenetics Global Limited announced board changes tied to its strategic pivot toward scaling IM8 as a global health and longevity brand. Director Kong Yiu (Andy) Cheung resigned effective February 16, 2026, a move the company said was aligned with its sharpened focus on IM8 and followed its December 4, 2025 decision to halt any future purchases of Bitcoin or other cryptocurrencies.
The company simultaneously appointed longevity expert and health-tech entrepreneur Dr. Darshan Shah as an independent director, effective February 16, 2026, adding him to its audit, compensation, and nominating committees. Shah’s background as a Mayo Clinic-trained surgeon, founder and CEO of Next Health, and nationally recognized product formulator is expected to reinforce Prenetics’ clinical rigor and commercial capabilities as it pursues data-driven clinical trials and global expansion of IM8’s science-backed product ecosystem.
Management framed these moves as strengthening board-level scientific and commercial oversight at a key inflection point for IM8’s growth. For investors and other stakeholders, the exit from crypto exposure and the addition of a high-profile longevity specialist underscore Prenetics’ commitment to its core consumer health strategy and to building long-term value around the IM8 platform.
The most recent analyst rating on (PRE) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page.
Spark’s Take on PRE Stock
According to Spark, TipRanks’ AI Analyst, PRE is a Neutral.
Overall score is constrained by weak financial performance (ongoing losses and negative operating/free cash flow), partially offset by strong technical trend and momentum. Valuation remains unattractive due to negative earnings and no dividend support.
To see Spark’s full report on PRE stock, click here.
More about Prenetics Group
Prenetics Global Limited (Nasdaq: PRE) is a consumer health sciences company focused on advancing human health and longevity through its flagship IM8 premium daily nutrition brand. Co-founded with David Beckham and endorsed by tennis world No. 1 Aryna Sabalenka, IM8 offers science-backed formulations such as its all-in-one Daily Ultimate Essentials supplement, and has rapidly scaled to over $100 million in annualized recurring revenue across more than 30 countries.
Average Trading Volume: 197,526
Technical Sentiment Signal: Hold
Current Market Cap: $369.7M
For a thorough assessment of PRE stock, go to TipRanks’ Stock Analysis page.